Page 1 |
Save page Remove page | Previous | 1 of 32 | Next |
|
small (250x250 max)
medium (500x500 max)
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
Subset |
PREDICTORS OF RESPONSE TO NEOADJUVANT THERAPY IN PATIENTS
WITH BREAST CANCER IN AN UNDERSERVED POPULATION
by
Ying Wang
A Thesis Presented to the
FACULTY OF THE USC GRADUATE SCHOOL
UNIVERSITY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
MASTER OF SCIENCE
(CLINICAL AND BIOMEDICAL INVESTIGATIONS)
December 2011
Copyright 2011 Ying Wang
Object Description
| Title | Predictors of response to neoadjuvant therapy in patients with breast cancer in an underserved population |
| Author | Wang, Ying |
| Author email | wang64@usc.edu;ywang.kate@yahoo.com |
| Degree | Master of Science |
| Document type | Thesis |
| Degree program | Clinical and Biomedical Investigations |
| School | Keck School of Medicine |
| Date defended/completed | 2011-10-12 |
| Date submitted | 2011-11-01 |
| Date approved | 2011-11-01 |
| Restricted until | 2011-11-01 |
| Date published | 2011-11-01 |
| Advisor (committee chair) | Azen , Stanley |
| Advisor (committee member) |
Wu, Anna Tripathy, Debu |
| Abstract | Purpose: Neoadjuvant therapy has became the standard of care in locally and advanced breast cancer, and is increasingly being used in early-stage breast cancer. The degree of pathologic response to treatment correlates with long-term outcome. The aims of this study were to identify clinical and pathologic characteristics that associated with pathologic complete response to neoadjuvant therapy and determine if different molecular subtypes of breast cancer respond differently to neoadjuvant treatment in patients with stage II and III breast cancer in an underserved and predominantly minority population. ❧ Methods: Using a single-institution database, 104 patients (82 Hispanics, 22 non-Hispanics) who received neoadjuvant therapy followed by surgery from January 2005 to December 2010 were included in this retrospective study. Patients were treated with chemotherapy alone or with trastuzumab. ER, PR and HER2 status were determined by the diagnostic core biopsy before treatment. Only a subset (n=45) of patients underwent BRCA gene testing. Chi-square or Fisher’s exact test was used to examine associations between pathologic complete response (pCR) and clinical-pathologic factors. Logistic regression analyses were performed to assess each variable contribution to pCR. ❧ Results: The overall pCR rate for this series was 27%. Six factors were associated with pCR in univariate analysis: age ≥50 years at diagnosis (p=0.047), clinical N0 node status (p=0.041), breast-conserving surgery (p<0.001), HER2 positive status (p<0.001), hormone receptor (HR) negative status (p=0.024) and molecular subtype (p=0.001). On multivariate analysis, molecular subtype was found to be an independent predictor of pCR to neoadjuvant therapy. The triple negative and HER2+ subtypes were associated with significantly higher rates of pCR, 23% and 44% respectively, whereas the HR+/HER2- subtypes had a pCR rate of 8.6% (p=0.001). HER2+ patients treated with neoadjuvant trastuzumab showed higher pCR rate than HER2+ patients not treated with neoadjuvant trastuzumab but this was not statistically significant (50% versus 27%; p=0.29). ❧ Conclusion: The pCR rate of this predominantly Hispanic cohort was comparable to results found in other studies. Molecular subtype was an independent predictive marker of pCR to preoperative therapy. The triple negative and HER2+ subtypes of breast cancer were significantly sensitive to preoperative therapy than the HR+/HER2- cancers. Addition of neoadjuvant trastuzumab for HER2+ tumors resulted in a superior response. |
| Keyword | breast cancer; neoadjuvant therapy; pathological response |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Provenance | Electronically uploaded by the author |
| Type | texts |
| Legacy record ID | usctheses-m |
| Rights | Wang, Ying |
| Access conditions | The author retains rights to his/her dissertation, thesis or other graduate work according to U.S. copyright law. Electronic access is being provided by the USC Libraries in agreement with the author, as the original true and official version of the work, but does not grant the reader permission to use the work if the desired use is covered by copyright. It is the author, as rights holder, who must provide use permission if such use is covered by copyright. The original signature page accompanying the original submission of the work to the USC Libraries is retained by the USC Libraries and a copy of it may be obtained by authorized requesters contacting the repository e-mail address given. |
| Repository name | University of Southern California Digital Library |
| Repository address | USC Digital Library, University of Southern California, University Park Campus MC 7002, 106 University Village, Los Angeles, California 90089-7002, USA |
| Repository email | cisadmin@usc.edu |
| Archival file | uscthesesreloadpub_Volume71/etd-WangYing-375.pdf |
Description
| Title | Page 1 |
| Full text | PREDICTORS OF RESPONSE TO NEOADJUVANT THERAPY IN PATIENTS WITH BREAST CANCER IN AN UNDERSERVED POPULATION by Ying Wang A Thesis Presented to the FACULTY OF THE USC GRADUATE SCHOOL UNIVERSITY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree MASTER OF SCIENCE (CLINICAL AND BIOMEDICAL INVESTIGATIONS) December 2011 Copyright 2011 Ying Wang |
Comments
Post a Comment for Page 1
